Trend Aggregation Conservative ETF TACE
Set alert
25.59 USD 0.00 0.00%
As of Sep 22, 3:59 PM ET
25.55 Day range 25.60
23.82 52-week range 25.83
- Open
- 25.59
- Prev close
- 25.59
- Mkt cap
- 16.01M
- Vol
- 5.79K
- Avg vol
- 11.09K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.55
- High
- 25.60
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 25.67
- 200-d avg
- 25.53
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 25.67
- 200-day average
- 25.53
About Trend Aggregation Conservative ETF
The investment seeks to provide total return. In pursuing the fund's investment objective, the fund will invest in ETFs that primarily invest in fixed income securities, real estate investment trusts ("REITs"), master limited partnerships ("MLPs"), dividend paying equity stocks including utility stocks, put options, U.S. treasuries and exchange-traded notes ("ETNs"). Fixed Income ETFs will include those that invest in domestic and foreign fixed income securities of any credit rating maturity and duration.
News
- IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
- Trend Aggregation Conservative ETF (NYSEARCA:TACE) Stock Price Down 0.2% – Time to Sell?
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- Trend Aggregation Conservative ETF (NYSEARCA:TACE) Shares Down 0.2% – Should You Sell?
- KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
- ETF Odds & Ends: 2 Closures Announced
- ETF Odds & Ends: Veterans Fund Closes
Your note
Sign in to keep a note on TACE — it syncs with the Stock Master app.